A Study of Baricitinib in Participants With Rheumatoid Arthritis
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2023
Locations: St Luke's Clinic - Intermountain Orthopaedics, Boise, Idaho
Conditions: Rheumatoid Arthritis
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
Recruiting
This investigator-initiated study will serve as a sub-study for the American College of Rheumatology-sponsored VERVE protocol currently funded by the NIH. This double-blinded multicenter randomized pragmatic trial is designed to determine whether Zostavax or Shingrix are safe and effective in patients with rheumatoid arthritis (RA) currently using anti-tumor necrosis factor (TNF) therapies. Inclusion/exclusion criteria for this sub-study mirror that of the parent VERVE trial with the exception o... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/16/2023
Locations: St. Luke's Health System, Boise, Idaho
Conditions: Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis